Abstract 130P
Background
In carcinoma esophagus patients where large volumes of lymphocyte producing organs and organs with circulating lymphocytes are exposed to radiation field, Radiation induced lymphopenia (RIL) is quite profound. Absolute Lymphocyte Count (ALC) has been postulated to have a crucial impact on treatment outcomes.In this study, dosimetric analysis on the organs at risk (OARs) for lymphopenia and its effect on pathological complete response (PCR) was assessed.
Methods
Carcinoma Esophagus patients who underwent neoadjuvant chemo-radiotherapy(NACT-RT) and definitive surgery from December 2018 to March 2021 were studied retrospectively. Data collected included baseline and weekly ALC, PCR on histopathology, mean dose (Dmean) and volume based dosimetry of the OARs for lymphopenia (thoracic vertebrae, bilateral lungs, liver, heart and spleen) and the effective dose to the circulating lymphocytes (EDIC), calculated using the formulae 0.12 (Dmean lung) + 0.08 (Dmean heart) + [0.45+ 0.35x 0.85(no of fractions/45ˆ1/2] Dmean body. PCR rates were correlated with ALC using Spearman’s correlation. Dosimetric parameters and EDIC was correlated with ALC using Pearson’s correlation test (p value<0.05).
Results
33 patient’s data who were eligible for the study was analysed. On Pearson’s correlation test the thoracic vertebrae Dmean (p-0.008) and V15 (p-0.012), liver Dmean (p-0.034) and V20 (p-0.038), heart Dmean (p-0.013) and V15 (p-0.022), spleen Dmean (p-0.040) were found to have significant correlation with ALC nadir. The mean EDIC was 6.21 (SD±5). No significant correlation between EDIC and ALC nadir was identified. 5% of patients did not achieve PCR at surgery. Spearman’s correlation test did not show a significant correlation between PCR and ALC nadir.
Conclusions
RIL has been demonstrated to have a negative impact on treatment outcomes. In our study, we discovered that dosimetric parameters of Dmean and volume based analysis of the OARs for lymphopenia were strongly correlated with ALC Nadir. Statistically significant correlation between ALC nadir and PCR rates was not seen. A larger multicentric study with a large number of patients, however, may be required to statistically prove our hypothesis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88P - Sintilimab plus anlotinib as second-line therapy for metastatic or recurrent gallbladder carcinoma (GBC): A single-arm, phase II study
Presenter: Qingbao Cheng
Session: Poster viewing 02
89P - Radiotherapy followed by camrelizumab for unresectable biliary tract cancer: A phase II clinical trial
Presenter: Zhenwei Peng
Session: Poster viewing 02
90P - Feasibility of using tumor-informed circulating tumor DNA (ctDNA)-based testing for patients with anal squamous cell carcinoma
Presenter: Georges Azzi
Session: Poster viewing 02
92P - Safety of liver resection following atezolizumab plus bevacizumab treatment in hepatocellular carcinoma (HCC) patients with macrovascular invasion: A pre-specified analysis of the TALENTop study
Presenter: Huichuan Sun
Session: Poster viewing 02
93P - Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Takuji Okusaka
Session: Poster viewing 02
94P - The treatment burden of neoadjuvant carboplatin/paclitaxel versus 5-fluorouracil/cisplatin in combination with radiotherapy for patients with esophageal cancer
Presenter: Chun-Ling Chi
Session: Poster viewing 02
95P - Additional survival follow-up of TACTICS-L: Transcatheter arterial chemoembolization therapy (TACE) in combination strategy with lenvatinib in (LEN) patients with unresectable hepatocellular carcinoma in Japan
Presenter: Yoshitaka Inaba
Session: Poster viewing 02
96P - Preoperative chemotherapy flot vs dox in patients of locally advanced gastric adenocarcinoma
Presenter: POORNIMA DEVI UTHAYAKUMAR
Session: Poster viewing 02
97P - BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma
Presenter: Nai-Jung Chiang
Session: Poster viewing 02